UK Markets close in 3 hrs 35 mins

Iovance Biotherapeutics, Inc. (0JDK.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
16.25-9.84 (-37.72%)
As of 4:32PM BST. Market open.
Sign in to post a message.
  • J
    James
    AGEN withdrew the Balstilimab AA filing in 2L cervical after the recent Keytruda approval. REGN's Libtayo will very likely gain approval in 2L soon, so will IOVA be able to file AA in the anti-PD-1 naïve setting even after resolving the essay issues?
  • G
    George
    Keytruda had sales of $14.3B in 2020 for an medium increase in life expectancy of about 9 months. IOVA had not yet reached median survival. Margins are much less on biologics due to manufacturing, but this will be huge.
  • C
    CTInvestor
    Is IOVA pull-back an ALLO-effect? Luckily the volume is low.
  • G
    Glenn
    Haven’t posted in several weeks. Looking for a positive? Take a look at the six month chart. Okay, We are coming off a miserable low @ $16 , but a nice slow build to $27. 68% up. Still, well off the $54 high. If we can get some news about a new CEO, maybe even a hint about assays, BLA, etc. then I think ( hope ) that we may be close to the 35-40 range by year end, maybe.
  • T
    TraditNow!
    Why is FATE valued 1B more than IOVA when IOVA has great data in two cancers, has manufacturing and is only waiting on an assay for fda submission? FATE is only phase 1.
  • t
    taxman
    Iovance will be first to market with a new first in class treatment. Hang on,be patient, and buy more.
  • s
    scott
    We should be able to make up for the losses and more within the next 15 months. Their first approval really shoul happen by the end of 2022.
  • L
    L
    About time this thing broke out.
  • J
    Jeffrey
    Ark still has a ton
    Only worry when they sell it all
  • s
    scott
    Some of the traders definitely seem to know certain key issues ahead of time.
  • j
    jsmith
    Crazy to be down pre-market, the press release on manufacturing capabilities should have moved us higher.
  • D
    Daniel
    Pray for a buyout
  • G
    G
    here comes the flood of data. Next stop RCC , the first tumor to be treated with interleukin therapy
  • I
    I Get By
    Cathie Wood may be selling but this is more important:

    8-29-21 Medscape: Two Metastatic Lung Cancer Patients Are Disease-Free for 1.5 Years after TILs. "Out of 16 patients, among 13 evaluable patients, 3 had confirmed responses and 11 had reduction in tumor burden. Two patients achieved complete responses that were ongoing 1.5 years following TIL treatment."

    These are lung cancer patients with no other good options.
  • E
    Erik
    Bad for healthcare costs, but the failure of the recent prescription/pharma drug price controls to get through the House of Reps may bode well for IOVA, LYEL, BLUE, TCRX, TCRR and other adoptive immune cell therapy companies whose drug products are likely to be quite expensive.
  • J
    Jeffrey
    Probably up today just because over sold
    TIL is also up
    Once the assays are approved into the 40s

    Then with first 2 approvals 100 and then bought out for 200 after they keeping inching up to 130
  • j
    jsmith
    Well, load up people. I'm selling half my shares for some rebalancing, every time I do this, this price goes up, and no, it doesn't help if I wait. Gotta do it now. You're welcome!
  • G
    Glenn
    Ark sold another 500k plus of shares today. I know some of you think this is trimming, but they are buying FATE hand over fist. So, they are betting on another horse. Own both so I’m hoping both succeed.
  • s
    salayandia
    I heard about IOVA the other day on (http://Rightpicker.com). It’s looking like an interesting play.